Hans Michael Kvasnicka
YOU?
Author Swipe
View article: Avapritinib reduces symptoms and mast cell burden in systemic mastocytosis
Avapritinib reduces symptoms and mast cell burden in systemic mastocytosis Open
Background Mastocytosis is driven by a clonal expansion of mast cells, commonly triggered by the KIT D816V mutation which is present in over 90% of adult patients. Individuals with indolent systemic mastocytosis (ISM) frequently experience…
View article: 87P Locoregional response and type of axillary surgery in patients who received neoadjuvant systemic therapy (NST): A retrospective multicenter analysis of 720 patients
87P Locoregional response and type of axillary surgery in patients who received neoadjuvant systemic therapy (NST): A retrospective multicenter analysis of 720 patients Open
Neoadjuvant systemic therapy (NST) is widely used in patients with breast cancer. Major advantages include locoregional response and adjustment of postneoadjuvant systemic therapy (PST). ALND remains the standard procedure for cN+ disease …
View article: Degenerative Changes in Aging Human Pelvic Lymph Nodes—A Reason to Rethink Staging and Therapy of Regional Malignancies?
Degenerative Changes in Aging Human Pelvic Lymph Nodes—A Reason to Rethink Staging and Therapy of Regional Malignancies? Open
Lymph node metastases are common in pelvic urological tumors, and the age-related remodeling process of the pelvic lymph nodes influences metastatic behavior. The aim of this work is to characterize age-related degenerative changes in the …
View article: Data from Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
Data from Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells Open
Antibody–drug conjugates (ADC) are emerging as powerful treatment strategies with outstanding target-specificity and high therapeutic activity in patients with cancer. Brentuximab vedotin represents a first-in-class ADC directed against CD…
View article: Supplementary Methods from Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
Supplementary Methods from Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells Open
PDF file - 97K
View article: Supplementary Figures 1 - 9, Table 1 from Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
Supplementary Figures 1 - 9, Table 1 from Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells Open
PDF file - 2651K, Supp. Fig. 1. Dolastatins induce phenotypic DC maturation in vitro. Supp. Fig. 2. Dolastatins induce phenotypic and functional maturation of BM-DCs in vitro. Supp. Fig. 3. Immuno-stimulatory effect of dolastatin 10 is ind…
View article: Supplementary Methods from Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
Supplementary Methods from Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells Open
PDF file - 97K
View article: Supplementary Figures 1 - 9, Table 1 from Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
Supplementary Figures 1 - 9, Table 1 from Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells Open
PDF file - 2651K, Supp. Fig. 1. Dolastatins induce phenotypic DC maturation in vitro. Supp. Fig. 2. Dolastatins induce phenotypic and functional maturation of BM-DCs in vitro. Supp. Fig. 3. Immuno-stimulatory effect of dolastatin 10 is ind…
View article: Data from Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells
Data from Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells Open
Antibody–drug conjugates (ADC) are emerging as powerful treatment strategies with outstanding target-specificity and high therapeutic activity in patients with cancer. Brentuximab vedotin represents a first-in-class ADC directed against CD…
View article: Influence of lymph node degeneration on metastases in prostate cancer: or why we must look for a needle in a haystack
Influence of lymph node degeneration on metastases in prostate cancer: or why we must look for a needle in a haystack Open
Background To evaluate the incidence of lymph node degeneration and its association with nodal metastatic pattern in prostate cancer. Methods A retrospective analysis of the submitted lymph node specimen of 390 prostatectomies in 2011 was …
View article: "Influence of lymph node degeneration on metastases in prostate cancer - or why we must look for a needle in a haystack"
"Influence of lymph node degeneration on metastases in prostate cancer - or why we must look for a needle in a haystack" Open
BackgroundTo evaluate the incidence of lymph node degeneration and its association with nodal metastatic pattern in prostate cancer. MethodsA retrospective analysis of the submitted lymph node specimen of 390 prostatectomies in 2011 was pe…
View article: International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data Open
The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology. Th…
View article: Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia
Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia Open
Essential thrombocythaemia (ET) is a rare myeloproliferative neoplasm. This multicentre, Phase 3b, randomised, open-label, non-inferiority study investigated the cardiac safety, efficacy and tolerability of first-line treatment with anagre…
View article: Human colon organoids reveal distinct physiologic and oncogenic Wnt responses
Human colon organoids reveal distinct physiologic and oncogenic Wnt responses Open
Constitutive Wnt activation upon loss of Adenoma polyposis coli (APC) acts as main driver of colorectal cancer (CRC). Targeting Wnt signaling has proven difficult because the pathway is crucial for homeostasis and stem cell renewal. To dis…
View article: Abstract 1500: The role of FUBP1 in the hematopoietic system and leukemia
Abstract 1500: The role of FUBP1 in the hematopoietic system and leukemia Open
The transcriptional regulator FUBP1 (Far Upstream Element Binding Protein 1) acts as an oncoprotein in hepatocellular carcinoma (HCC) and is important for hematopoietic stem cell (HSC) self-renewal and erythroid maturation in mice. In this…
View article: Increased tumor vascularization is associated with the amount of immune competent PD‑1 positive cells in testicular germ cell tumors
Increased tumor vascularization is associated with the amount of immune competent PD‑1 positive cells in testicular germ cell tumors Open
Testicular germ cell cancer in a metastatic state is curable with a cisplatin-based first line chemotherapy. However, 10-15% of these patients are resistant to first line chemotherapy and are thus left with only palliative options. Immunot…
View article: Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature
Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature Open
Selective BRAF inhibitors such as vemurafenib have become a treatment option in patients with Langerhans cell Histiocytosis (LCH). To date, only 14 patients receiving vemurafenib for LCH have been reported. Although vemurafenib can stabili…
View article: Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis Open
INCB18424-251, ClinicalTrials.gov identifier NCT00509899 .